US2016136127A1PendingUtilityA1

Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour

Assignee: GW PHARMA LTDPriority: Jun 19, 2013Filed: Jun 19, 2014Published: May 19, 2016

Est. expiryJun 19, 2033(~6.9 yrs left)· nominal 20-yr term from priority

Inventors:Wai Liu Katherine Scott Angus Dalgleish Marnie Duncan Colin Stott

A61P 35/00A61K 45/06A61K 36/3482A61K 31/658A61K 31/352A61K 36/185A61K 31/05

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.

Claims

exact text as granted — not AI-modified

1 . A method for treatment of a brain tumour comprising administering the phytocannabinoids tetrahydrocannabinol (THC and/or cannabidiol (CBD) to increase radiosensitivity in the treatment of a brain tumour. 
     
     
         2 . The method as claimed in  claim 1 , wherein the brain tumour is a glioma tumour. 
     
     
         3 . The method as claimed in  claim 1 , wherein the brain tumour is a glioblastoma multiforme (GBM). 
     
     
         4 . The method as claimed in  claim 1 , wherein the phytocannabinoids are in the form of an extract or botanical drug substance. 
     
     
         5 . The method as claimed in  claim 1 , wherein the phytocannabinoids are in an isolated or pure form. 
     
     
         6 . A method for treatment of a brain tumour comprising administering a combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) to increase radiosensitivity in the treatment of a brain tumour.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.